Neumora Therapeutics Inc. has patented NMDA receptor positive allosteric modulators reported to be useful for the treatment of autoimmune disease, infections, neurological and psychiatric disorders.
Bad news has buffeted Sage Therapeutics Inc. twice in the past few months. Now its placebo-controlled phase II Lightwave study of dalzanemdor in Alzheimer's disease has missed the primary outcome measure, prompting the company to stop development of the NMDA receptor positive allosteric modulator in the indication.
